Pharmaceutical

Amgen receives FDA priority review for tarlatamab BLA

Amgen has received US FDA priority review for its biologics licence application for tarlatamab to treat advanced small-cell lung cancer.

Dec 14, 2023 - 18:00
Amgen receives FDA priority review for tarlatamab BLA
Amgen has received US FDA priority review for its biologics licence application for tarlatamab to treat advanced small-cell lung cancer.
Read the original article

Tags:

Previous Article

Abbisko tenosynovial giant cell tumour therapy gains fast track status

Next Article

FDA Approves Gene Therapies for Sickle Cell Treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Court strikes down Trump-era rule that allowed health insurers to broadly use copay accumulators

STAT+: Court strikes down Trump-era rule that allowed h...

Oct 2, 2023

Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I

Vicebio secures $100m to advance RSV and hMPV vaccine c...

Sep 24, 2024

Amylyx ventures into metabolic diseases market with $35.1m deal

Amylyx ventures into metabolic diseases market with $35...

Jun 30, 2024